Literature DB >> 11446734

Pure red cell aplasia after ABO-incompatible allogeneic stem cell transplantation in severe aplastic anemia with response to steroids: a case report and literature review.

M H Yang1, H C Hsu.   

Abstract

Pure red cell aplasia (PRCA) is a rare complication after ABO-incompatible allogeneic stem cell transplantation, but its mechanism is still unknown. Here we report on a patient with severe aplastic anemia who developed PRCA after HLA-identical but major ABO-mismatched peripheral blood stem cell transplantation. Erythroid engraftment was successful with primary steroid treatment. We concluded that an adequate dose of steroids can be the first line of therapy for PRCA after ABO-mismatched allogeneic stem cell transplantation.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11446734     DOI： 10.1007/s002770000275

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


  6 in total

1.  Pulsed-high-dose dexamethasone as a treatment for pure red cell aplasia following ABO-incompatible allogeneic stem cell transplantation.

Authors:  X Yang; M Levis
Journal:  Transfus Med       Date:  2014-08       Impact factor: 2.019

2.  Oral High Dose Dexamethasone for Pure Red Cell Aplasia Following ABO-Mismatched Allogeneic Peripheral Blood Stem Cell Transplantation: A Case Report.

Authors:  Sanjeev Kumar Sharma; Suman Kumar; Narendra Agrawal; Pravas Mishra; Tulika Seth; Manoranjan Mahapatra
Journal:  Indian J Hematol Blood Transfus       Date:  2013-06-09       Impact factor: 0.900

Review 3.  Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question.

Authors:  Javier Marco-Ayala; Inés Gómez-Seguí; Guillermo Sanz; Pilar Solves
Journal:  Bone Marrow Transplant       Date:  2020-11-14       Impact factor: 5.483

4.  Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins.

Authors:  Georg Stussi; Jörg Halter; Eveline Bucheli; Piero V Valli; Lutz Seebach; Jürg Gmür; Alois Gratwohl; Urs Schanz; Jakob R Passweg; Jörg D Seebach
Journal:  Haematologica       Date:  2009-01-14       Impact factor: 9.941

5.  The effect of donor leukocyte infusion on refractory pure red blood cell aplasia after allogeneic stem cell transplantation in a patient with myelodysplastic syndrome developing from Kostmann syndrome.

Authors:  Yasuhiro Ebihara; Atsushi Manabe; Toshihisa Tsuruta; Kumiko Ishikawa; Daisuke Hasegawa; Yoshitoshi Ohtsuka; Hirohide Kawasaki; Kazuo Ogami; Yuka Wada; Tadayasu Kanda; Kohichiro Tsuji
Journal:  Int J Hematol       Date:  2007-12       Impact factor: 2.490

6.  Successful Treatment of Pure Red Cell Aplasia with Rituximab in Patients after ABO-Compatible Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Sung-Hoon Jung; Jae-Sook Ahn; Deok-Hwan Yang; Hyung Chul Park; Soo-Young Bae; Yeo-Kyeoung Kim; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Case Rep Oncol       Date:  2012-02-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.